je.st
news
Analyst: In Merck-Idenix deal, 'biggest question' is why Gilead wasn't the suitor
2014-06-18 21:04:16| Biotech - Topix.net
If Merck & Co .' s $4 billion bet on the hepatitis C drug being developed by Cambridge biotech firm Idenix Pharmaceuticals pays off, it will provide Merck with a slice of an estimated $50 billion market over the next decade.
Tags: the
question
deal
biggest
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||